|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferrone CR, Brennan MF, Gonen M, et al:
Pancreatic adenocarcinoma: The actual 5-year survivors. J
Gastrointest Surg. 12:701–706. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Burris HA III, Moore MJ, Andersen J, et
al: Improvements in survival and clinical benefit with gemcitabine
as first-line therapy for patients with advanced pancreas cancer: A
randomized trial. J Clin Oncol. 15:2403–2413. 1997.PubMed/NCBI
|
|
4
|
Hagmann W, Jesnowski R and Löhr JM:
Interdependence of gemcitabine treatment, transporter expression,
and resistance in human pancreatic carcinoma cells. Neoplasia.
12:740–747. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
McBride WG: Thalidomide embryopathy.
Teratology. 16:79–82. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
D'Amato RJ, Loughnan MS, Flynn E and
Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl
Acad Sci USA. 91:4082–4085. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Singhal S, Mehta J, Desikan R, et al:
Antitumor activity of thalidomide in refractory multiple myeloma. N
Engl J Med. 341:1565–1571. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rezvani H, Haghighi S, Ghadyani M and
Attarian H: Efficacy of taxotere, thalidomide, and prednisolone in
patients with hormone-resistant metastatic prostate cancer. Urol J.
9:673–677. 2012.PubMed/NCBI
|
|
9
|
Lv J, Liu N, Liu KW, et al: A Randomised
Controlled Phase II Trial of the Combination of XELOX with
Thalidomide for the First-line Treatment of Metastatic Colorectal
Cancer. Cancer Biol Med. 9:111–114. 2012.PubMed/NCBI
|
|
10
|
Lee SM and Hackshaw A: A potential new
enriching trial design for selecting non-small-cell lung cancer
patients with no predictive biomarker for trials based on both
histology and early tumor response: Further analysis of a
thalidomide trial. Cancer Med. 2:360–366. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
de Souza CM, Araújo e Silva AC, de Jesus
Ferraciolli C, et al: Combination therapy with carboplatin and
thalidomide suppresses tumor growth and metastasis in 4T1 murine
breast cancer model. Biomed Pharmacother. 68:51–57. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tunio MA, Hashmi A, Qayyum A, Naimatullah
N and Masood R: Low-dose thalidomide in patients with metastatic
renal cell carcinoma. J Pak Med Assoc. 62:876–879. 2012.PubMed/NCBI
|
|
13
|
Dmoszynska A, Podhorecka M, Manko J, et
al: The influence of thalidomide therapy on cytokine secretion,
immunophenotype, BCL-2 expression and microvessel density in
patients with resistant or relapsed multiple myeloma. Neoplasma.
52:175–181. 2005.PubMed/NCBI
|
|
14
|
Marriott JB, Clarke IA, Czajka A, et al: A
novel subclass of thalidomide analogue with anti-solid tumor
activity in which caspase-dependent apoptosis is associated with
altered expression of bcl-2 family proteins. Cancer Res.
63:593–599. 2003.PubMed/NCBI
|
|
15
|
Georgakoudi I, Solban N, Novak J, et al:
In vivo flow cytometry: a new method for enumerating circulation
cancer cells. Cancer Res. 64:5044–5047. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Forni M: Laboratory animals science: a
resource to improve the quality of science. Vet Res Commun.
31:Suppl 1. 43–47. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yabu T, Tomimoto H, Taguchi Y, et al:
Thalidomide-induced antiangiogenic action is mediated by ceramide
through depletion of VEGF receptors, and is antagonized by
sphingosine-1-phosphate. Blood. 106:125–134. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang ZL, Liu ZS and Sun Q: Effects of
thalidomide on angiogenesis and tumor growth and metastasis of
human hepatocellular carcinoma in nude mice. World J Gastroenterol.
11:216–220. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Steins MB, Padró T, Bieker R, et al:
Efficacy and safety of thalidomide in patients with acute myeloid
leukemia. Blood. 99:834–839. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu WM, Strauss SJ, Chaplin T, et al:
s-thalidomide has a greater effect on apoptosis than angiogenesis
in a multiple myeloma cell line. Hematol J. 5:247–254. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Estaquier J, Vallette F, Vayssiere JL and
Mignotte B: The mitochondrial pathways of apoptosis. Adv Exp Med
Biol. 942:157–183. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shen J, Wan R, Hu G, et al: miR-15b and
miR-16 induce the apoptosis of rat activated pancreatic stellate
cells by targeting Bcl-2 in vitro. Pancreatology. 12:91–99. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sung KF, Odinokova IV, Mareninova OA, et
al: Prosurvival Bcl-2 proteins stabilize pancreatic mitochondria
and protect against necrosis in experimental pancreatitis. Exp Cell
Res. 315:1975–1989. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Barbu A, Welsh N and Saldeen J:
Cytokine-induced apoptosis and necrosis are preceded by disruption
of the mitochondrial membrane potential (Deltapsi(m)) in pancreatic
RINm5F cells: Prevention by Bcl-2. Mol Cell Endocrinol. 190:75–82.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Aydoğan S, Celiker U, Türkçüoğlu P, Ilhan
N and Akpolat N: The effect of thalidomide on vascular endothelial
growth factor and tumor necrosis factor-alpha levels in retinal
ischemia/reperfusion injury. Graefes Arch Clin Exp Ophthalmol.
246:363–368. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Coultas L, Chawengsaksophak K and Rossant
J: Endothelial cells and VEGF in vascular development. Nature.
438:937–945. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Giatromanolaki A, Koukourakis MI,
Stathopoulos GP, et al: Angiogenic interactions of vascular
endothelial growth factor, of thymidine phosphorylase, and of p53
protein expression in locally advanced gastric cancer. Oncol Res.
12:33–41. 2000.PubMed/NCBI
|
|
28
|
Xu C, Wu A, Zhu H, et al: Melatonin is
involved in the apoptosis and necrosis of pancreatic cancer cell
line SW-1990 via modulating of Bcl-2/Bax balance. Biomed
Pharmacother. 67:133–139. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Colucci G, Labianca R, Di Costanzo F, et
al: Gruppo Oncologico Italia Meridionale (GOIM); Gruppo Italiano
per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD);
Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC): Randomized
phase III trial of gemcitabine plus cisplatin compared with
single-agent gemcitabine as first-line treatment of patients with
advanced pancreatic cancer: The GIP-1 study. J Clin Oncol.
28:1645–1651. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Herrmann R, Bodoky G, Ruhstaller T, et al:
Swiss Group for Clinical Cancer Research; Central European
Cooperative Oncology Group: Gemcitabine plus capecitabine compared
with gemcitabine alone in advanced pancreatic cancer: A randomized,
multicenter, phase III trial of the Swiss Group for Clinical Cancer
Research and the Central European Cooperative Oncology Group. J
Clin Oncol. 25:2212–2217. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Abou-Alfa GK, Letourneau R, Harker G, et
al: Randomized phase III study of exatecan and gemcitabine compared
with gemcitabine alone in untreated advanced pancreatic cancer. J
Clin Oncol. 24:4441–4447. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chauffert B, Mornex F, Bonnetain F, et al:
Phase III trial comparing intensive induction chemoradiotherapy (60
Gy, infusional 5-FU and intermittent cisplatin) followed by
maintenance gemcitabine with gemcitabine alone for locally advanced
unresectable pancreatic cancer. Definitive results of the 2000-01
FFCD/SFRO study. Ann Oncol. 19:1592–1599. 2008. View Article : Google Scholar : PubMed/NCBI
|
